WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell® Wearable
Pain Relief Technology™, reported purchases during May 2016
of the company's common stock by its Chief Executive Officer, Dr. Shai
N. Gozani; its Chief Financial Officer, Thomas T. Higgins; and its SVP
and General Manager, Consumer, Frank McGillin. Details of these
transactions may be found on the U.S. Securities and Exchange
Commission's EDGAR website at the following links:
Form
4 SNG 5/18/2016
Form
4 TTH 5/18/2016
Form
4 FXM 5/23/2016
About Quell
Quell utilizes NeuroMetrix's patented neurostimulation technology to
provide widespread relief from chronic pain. The advanced wearable
device is lightweight and can be worn during the day while active, and
at night while sleeping. It has been cleared by the FDA for treatment of
chronic pain without a prescription. In a recent study, 81% of Quell
users reported an improvement in their chronic pain. Quell includes a
smartphone app that tracks and personalizes their pain therapy. Quell
was recently awarded the Innovation Award at SXSW for best Wearable
Technology. It is available for purchase at www.QuellRelief.com,
selected retailers and healthcare professionals.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160610005595/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
